Navigation Links
Heptares to Present at Upcoming Biotech Industry Conferences
Date:6/6/2013

WELWYN GARDEN CITY, England and BOSTON, June 6, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be presenting at the following biotech industry events over the coming weeks.

EPIC European Partnering and Investment Conference (London, UK, 6 June)

Dr Barry Kenny , Heptares' Chief Business Officer, will present an overview of the Company at 4:00pm (BST).  

Boston Biotech CEO Conference (Boston, MA, USA, 11-12 June)

Mr Dan Grau , Heptares' President, will participate in a panel discussion entitled Building Technology Value: A Checklist of Essentials, at 10:30am (EDT) on 12 June.

For a full list of events at which Heptares will be present, please visit http://www.heptares.com  

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit htt
'/>"/>

SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda
2. Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
3. Heptares to Moderate Panel on Rare Diseases at BBC New York CEO Meeting (13-14 February)
4. Heptares to Present at BIO-Europe 2012
5. Heptares Solves First Family B GPCR Structure
6. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
7. Hadasit Bio-Holdings Ltd. to Present at the Third Annual Connecticut-Israel Technology Summit
8. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
9. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
10. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
11. Caris Life Sciences ASCO Presentation Highlights the Utility of Molecular Profiling for the Management of Rare and Aggressive Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 Follow us ... of each type of cholesterol carrier or lipoprotein in ... of excessive cholesterol levels in the body, especially along ... to heart attack and other cardiovascular disorders. Cardiovascular Diseases ... testing for cholesterol levels on a regular basis, to ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)... Sept. 30, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 ... Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid ... Use Thereof." The patent, which extends ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... products coming soon to Bioniche,s growing line of injectable ... ... Bioniche Pharma, a leading,developer and manufacturer of injectable pharmaceuticals, announced today,the acquisition ... chloride injection, USP) 10 mg/mL, 15 mL vial -- ENLON-PLUS(R) (edrophonium ...
... Moore named as Vice President, Marketing and Sales; Susan Koppy ... named as Vice President, Corporate Development, PT. ... appointment of Terrence Moore to the position of,Vice President, Marketing ... Corporate Development. Both Mr. Moore and Ms. Koppy will report,to ...
... based on cells manufactured from bone ... round, SALT LAKE CITY and HAMBURG, Germany, July ... of innovative cell therapies,for the treatment of acute kidney ... financing. The round was led by SV Life Sciences ...
Cached Biology Technology:Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R) 2Transcept Pharmaceuticals Appoints Key Senior Executives 2Transcept Pharmaceuticals Appoints Key Senior Executives 3Transcept Pharmaceuticals Appoints Key Senior Executives 4AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3
(Date:9/30/2014)... new research, involving mice and published in the October ... Biology , suggests that just because you can ... a team of Italian scientists have found that using ... the immune system. This damage may result in autoimmune ... inflammatory bowel disease and rheumatoid arthritis in adulthood. , ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/29/2014)... A new study confirms that the exposure to tar ... than of regular cigarettes. Similarly, exposure to nicotine ... increasingly popular type of cigarette in several countries around ... of certain toxic chemicals in the smoke of these ... because lower levels of chemicals in the smoke are ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... differences account for some of the most of the spectacular ... plumage of peacocks, tusks on walruses and antlers on moose. ... mating is thought to be a particularly potent force ... females. However, the genetic processes responsible for producing such ...
... PAUL (05/03/2012) Vegetation, such as a patch of prairie or ... when more plant species are present, a new University of ... found that each species plays a role in maintaining a ... The study found that every additional species in a plot ...
... of California, Berkeley, scientists are drilling into ancient sediments ... clues that could help them better predict how today,s ... increasing population. The lake sediments are among the ... as far as 500,000 years. The core drilling ...
Cached Biology News:Biologists turn back the clock to understand evolution of sex differences 2Plant diversity is key to maintaining productive vegetation, U of M study shows 2Scientists core into California's Clear Lake to explore past climate change 2Scientists core into California's Clear Lake to explore past climate change 3Scientists core into California's Clear Lake to explore past climate change 4
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: